• 1
    Malaguarnera M, DiFazio I, Restuccia S, et al. Efficacy of different schedules in the management of chronic hepatitis C with interferon-alpha. Ann Med 1998; 30: 21317.
  • 2
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 148592.
  • 3
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks vs. interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 142632.
  • 4
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 95865.
  • 5
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 6
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon α-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 7
    Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 55667.
  • 8
    Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12: 195202.
  • 9
    Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987; 316: 58996.
  • 10
    Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001; 15: 41929.
  • 11
    Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res 2001; 21: 110315.
  • 12
    Wang YS, Youngster S, Bausch J, et al. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000; 39: 1063440.
  • 13
    Peginterferon alfa-2b Product Information. Kenilworth, NJ, USA: Schering Corporation.
  • 14
    Peginterferon alfa-2a Complete Product Information. Nutley, NJ, USA: Roche Pharmaceuticals.
  • 15
    Lamb MW, Martin NE. Weight based dosing vs. fixed dosing of peginterferon (40 kDa) alfa-2a. Ann Pharmacother 2002; 36: 9335.
  • 16
    Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 166672.
  • 17
    Jen JF, Glue P, Ezzet F, et al. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin Pharmacol Ther 2001; 69: 40721.
  • 18
    Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 19
    Flamm SL, Cahan J, Goldman J, et al. PEG IFN α 2b 1.0 mcg/kg/wk + ribavirin is equally as effective as PEG IFN α 2b 1.5 mcg/kg/wk +  ribavirin: preliminary results from a prospective, randomized, controlled, multi-center trial. Gastroenterology 2003; 124 (Suppl. 1): 212A.
  • 20
    Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 110915.
  • 21
    Modi MW, Fulton JS, Buckmann DK, et al. Clearance of pegylated (40 kDa) interferon alfa-2a (Pegasys) is primarily hepatic. Hepatology 2000; 34: 317A.
  • 22
    Martin P, Mitra S, Farrington K. Pegylated (40 kD) interferon alfa-2a (Pegasys) is unaffected by renal impairment. Hepatology 2000; 32: 370A.
  • 23
    Lamb MW, Marks IM, Wynohydradnyk L, et al. Peginterferon alfa-2a (40 kD) can be administered safely in patients with end-stage renal disease. Hepatology 2001; 34: 326A.
  • 24
    FDA. Antiviral Drugs Advisory Committee Proceedings. Peginterferon alfa-2b, December 12, 2001,
  • 25
    FDA. Antiviral Drugs Advisory Committee Proceedings. Peginterferon alfa-2a, November 14, 2002,
  • 26
    Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 158286.
  • 27
    Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 22631.
  • 28
    Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 1037.
  • 29
    Zeuzem S, Hermann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 143847.
  • 30
    Hermann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37: 135158.
  • 31
    Formann E, Jessner W, Bennett L, et al. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003; 10: 27176.
  • 32
    Lutchman G, Hoofnagle JH. Viral kinetics in hepatitis C. Hepatology 2003; 37: 125759.
  • 33
    Zeuzem S, Pawlotsky J-M, Hagai E, et al. International, multicenter, randomized, controlled study comparing standard vs. dynamically individualized treatment in patients with chronic hepatitis C (DITTO-HCV Project). Hepatology 2002; 38 (Suppl. 1): 310A.